UNSPSC 51292100: Antidepressant anthracenes

Antidepressant drugs made from A group of compounds with three aromatic rings joined in linear arrangement.

UNSPSC 51292100 Antidepressant anthracenes is a Class code that in practice covers pharmaceutical procurement across state and local health systems, though recent solicitations show limited activity specifically targeting this drug class. The code encompasses the supply of antidepressant medications and related pharmaceutical products to state agencies, county health departments, and regional purchasing cooperatives. State and local governments buying under this code typically procure pharmaceuticals through formal competitive bidding, cooperative purchasing agreements with authorized wholesalers, and pharmacy benefit program initiatives. Issuing bodies include state health and human services commissions, county health departments, and multistate cooperative purchasing alliances that aggregate demand across member jurisdictions to achieve volume discounts and standardized sourcing.

Recent opportunities show activity concentrated in Florida and Minnesota, with exploratory procurement in Texas. Seminole County, Florida released IFB 60459723LAS in June 2026 to procure naloxone and drug deactivation systems through quarterly deliveries with an initial two-year term and renewal option; while this solicitation addresses opioid response rather than antidepressants directly, it signals county-level pharmaceutical procurement infrastructure. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 to establish contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026; MMCAP requires vendors to work through three authorized wholesalers and maintain pricing flexibility across multiple formats. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs, an early-stage exploration that may lead to formal solicitation. Recent competitive activity emphasizes cGMP and DSCSA compliance, EDI capability, and pricing competitiveness as primary evaluation factors.